Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicinal Use of Leonurine for Menopausal Disorders

A technology of motherwort and medicine, applied in the field of medicine, can solve the problems of increasing myocardial infarction and thrombosis and the like

Active Publication Date: 2012-02-01
李晓祥
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no drug with small side effects and significant curative effect, and estrogen replacement therapy (hormone replacement treatment, HRT) is commonly used clinically, but adverse reactions caused by HRT continue to appear, such as estrogen and progesterone increase myocardial infarction, stroke, The long-term use of HRT has been questioned internationally due to the risk of breast cancer and thrombosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal Use of Leonurine for Menopausal Disorders
  • Medicinal Use of Leonurine for Menopausal Disorders
  • Medicinal Use of Leonurine for Menopausal Disorders

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Example 1: Leonurine on serum TSH and FT of menopausal model rats 3 , FT 4 Impact

[0020] According to the above experiments, the effect of leonurine on serum TSH and FT of menopausal model rats 3 , FT 4 The results are shown in Table 1.

[0021] Table 1 Leonurine on TSH and FT in menopausal rats 3 , FT 4 Effect of (x±S, n=8)

[0022]

[0023] ▲ P<0.05vs youth control group, *p<0.05vs menopause model group

[0024] Table 1 illustrates the TSH and FT of rats in the menopause model group 3 The secretion level was significantly higher than that of the young control group ( ▲ P3 Both medium and high doses of Leonurine significantly reduced TSH and FT in the model group rats 3 Level (*p4 Levels were not associated with menopausal syndrome, while leonurine had no effect on FT 4 level has little effect. It shows that motherwort can significantly prevent, alleviate or treat menopausal syndrome.

Embodiment 2

[0025] Example 2: The effect of leonurine on NE, DA, 5-HT and 5-HIAA in the hypothalamus of menopausal model rats

[0026] According to the above experiment, the effect of leonurine on NE, DA, 5-HT, 5-HIAA in the hypothalamus of the menopausal model rats, the results are shown in Tables 2 and 3.

[0027] Table 2 The effect of leonurine on the contents of NE and DA in menopausal rats (x±S, n=8)

[0028]

[0029] ▲ P<0.05vs youth control group, *p<0.05vs menopause model group

[0030] Table 2 shows that the NE secretion level of the menopausal model group was significantly lower than that of the young control group ( ▲ P<0.05vs the youth control group); Leonurine can both increase the NE level of the model group rats, and high-dose Leonurine can significantly increase the NE level of the model group rats (*p<0.05vs the menopause model group); There was no significant difference in the DA levels of the mice. It shows that motherwort can significantly prevent, alleviate or ...

Embodiment 3

[0035] Example 3: The effect of leonurine on serum E2 and P of climacteric model rats

[0036] According to the above experiment, the effect of leonurine on serum E of menopausal model rats 2 , P, the results are shown in Table 4.

[0037] Table 4 Leonurine on serum E of menopausal rats 2 , the effect of P (x±S, n=8)

[0038]

[0039] ▲ P<0.05vs youth control group, *p<0.05vs menopause model group

[0040] Table 4 illustrates the menopause model group rat E 2 The secretion levels of P and P were significantly lower than those of the young control group ( ▲ P2secretion level, high-dose Leonurine significantly increased the E of the model group animals 2 and P secretion level (*p<0.05vs menopause model group), this result suggests that leonurine can relieve the symptoms of menopausal syndrome and increase the levels of estrogen and progesterone in menopausal rats.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the medical use of motherwort for menopausal diseases. Specifically, the present invention provides the medical use of motherwortine or its pharmaceutically acceptable salt for preventing or treating climacteric syndrome and diseases related to climacteric syndrome.

Description

Technical field: [0001] The invention belongs to the field of medicine, and relates to a new medicinal use of leonurine. Specifically, the present invention provides new uses of leonurine for preventing or treating climacteric syndrome and disorders related to climacteric syndrome. Background technique: [0002] Motherwort, also known as Leonurus heterophyllus Sweet, is a Lamiaceae plant of the genus Motherwort and is the most common medicinal plant in my country. Its Latin scientific name is Leonurus heterophyllus Sweet. , removing blood stasis, regulating menstruation, and eliminating water, it is known as "the holy medicine for blood vessels" and "prescription for menstruation". [0003] Motherwort is the main active substance of motherwort, which only contains less than 5‰ in crude drug, and the extraction process is complicated. There are artificially synthesized leonurine and its medicinal salts, such as Chinese published patent document CN1415602A. CN1415603A also d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/235A61P15/12
Inventor 李晓祥李德刚徐自奥王显芹李爱玲
Owner 李晓祥
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com